Condition: KRAS P.G12D · Sponsor: D3 Bio (Wuxi) Co., Ltd
This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
This description comes directly from the study's public registry record.
Medical Director · +86 21 61635900 · D3bio_CT@d3bio.com
Always discuss trial participation with your own doctor first.
| D3 Bio Investigative Site 1402 | San Antonio, Texas, United States | Recruiting |
| D3 Bio Investigative Site 1103 | Randwick, New South Wales, Australia | Recruiting |
| D3 Bio Investigative Site 1201 | Seoul, South Korea | Recruiting |
| D3 Bio Investigative Site 1203 | Seoul, South Korea | Recruiting |
| D3 Bio Investigative Site 1202 | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07456046